KEYNOTE-028-158
Regimen
- Experimental
- pembrolizumab monotherapy (10 mg/kg q2w or 200 mg q3w)
- Control
- no control (single-arm pooled)
Population
Recurrent or metastatic SCLC previously treated with ≥2 lines of therapy
Key finding
ORR 19.3% (95% CI 11.4-29.4); 2 CR + 14 PR; 61% of responders had DOR ≥18 mo
Source: PMID 31870883
Timeline
Guideline citations
- NCCN SCLC (p.6)